Latest Information

20.11.08 - Latest NAV performance

13.11.08 - Investment Bulletin

12.11.08 - Latest Fund Factsheets

07.11.08 - Pick of the Week

05.11.08 - 'Old Europe'

 

Fund Prices (20 Nov 2008)

A Share

£  88.41

£130.57

£132.16

£  81.01

£101.77

£  64.08

B Share

£  86.36

£128.05

£130.84

£  76.25

£101.03

£108.86

Funds under Management - £176.7 million

Unlike most fund management companies, Bedlam is structured to make investors money

Bedlam is structured to make investors money

      Pick of the Week

Bedlam is structured to make investors money Articles    
Bedlam is structured to make investors money Financials

Japan Stock Writeups

 

Central Japan Railway operates the high-speed Shinkansen rail service between Tokyo and Osaka as well as lower-speed local trains in the same region. It also has related merchandise and real-estate businesses. The Shinkansen is faster than air travel on the Tokyo-Osaka route and takes a similar amount of time on the Tokyo-Okayama route (after allowing for airport check-in etc.); it is also considerably kinder to the environment. However, air travel still captures a significant market share on these routes, in particular the Okayama route. The company is well positioned in an area with a growing population and improving economics, has achieved a high return on equity in the past and has shown steady profit growth over the last five years. The current share price is overly depressed as yield-focussed investors have been selling following the announcement of a planned new Tokyo-Chukyo line, which will reduce the level of surplus cash flow over the next 20 years.

Sedol Type Price Date
6183552 Buy JPY 1,025,454 13 February 2008

 

Chiba Bank. This regional bank announced strong 1H04 results on the back of an improvement in asset quality. During the downturn Chiba was hit particularly hard due to its extensive exposure to property. Hence on an upturn it has most to benefit. It's 1H04 numbers were upgraded by over 40%. In line with sector expectations consensus believes growth is not sustainable as there will be no improvement in loan growth and the asset quality improvement will dissipate. We think they're wrong. Regional banks such as Chiba have the greatest exposure to the small medium sized corporate sector. This is the sector in Japan that is showing the fastest improvement. We expect FY03/04 and FY03/05 earnings to surprise significantly on the upside.  

Sedol Type Price Date
6190563 Buy JPY 1033.50 11/04/2006
6190563 Buy JPY 975.50 28/02/2006
6190563 Buy JPY 1011.439 28/11/2005
6190563 Buy JPY 979.531 24/10/2005
6190563 Buy JPY 825.417 12/09/2005
6190563 Buy JPY  797.286 16/08/2005
6190563 Buy JPY 716.980 28/07/2005
6190563 Buy JPY 724.087 12/07/2005
6190563 Buy JPY 732.091 30/06/2005
6190563 Buy JPY 688.5 01/02/2005
6190563 Buy JPY 688.7 24/01/2005
6190563 Buy JPY 700.75 16/11/2004
6190563 Buy JPY 680.20 15/11/2004
6190563 Buy JPY 696.75 05/11/2004
6190563 Buy JPY 705.667 04/11/2004
6190563 Buy JPY 683.90 01/11/2004

 

Chiyoda's first quarter results made for grim reading, with margins collapsing in the face of their inability to pass on cost-hikes to their customers - the outturn was far worse than management had previously indicated. With margins falling and cashflow tight, we sold.

Chiyoda is a leading global player in the liquid natural gas (LNG) construction industry, with a market share of 45%. Demand for LNG is strong and the company has lucrative contracts in Qatar. In addition Japan is undergoing a large switch away from oil and towards LNG. Chiyoda is well placed to meet this rising demand.

Sedol Type Price Date
6191704 Sell JPY 2076.59 08/08/2007
6191704 Buy JPY 2509.00 21/06/2007


 

 

Chugai Pharma. Support for the company's earnings will be driven by many new drugs coming through its pipeline, with the company a 50% subsidiary of Roche. As it sells Tamiflu in Japan, it benefits from the government confirming that there is no relationship between Tamiflu and abnormal behaviour in children. This bodes well for winter sales. In addition the company has two new drug launches over the next 12 months which should provide a boost. In November it filed with for FDA approval to sell Actemra (an arthritis drug), with approval in Europe set for December.

Sedol Type Price Date
6196408 Buy JPY 1837.422 26/11/2007

Back to Japan Stock Writeups categories View Latest Transactions

back to japan portfolio

 

View Stocks A - Z

Home
About Bedlam
Investors
Funds
Segregated Accounts
News
Archive
Financials
Contact Bedlam
www.intergage.co.uk